Zhaoke Ophthalmology is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise while designing the pipeline, the Company has initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Up to now, the Company has built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing.
TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final DJ EQS-News: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final EQS-News / 16/04/2021 / 11:26 UTC+8 Zhaoke Ophthalmology Limited (6622.HK) Launches Its HKPO with 8 Cornerstone Investors to Fuel Its Future Growth (April 16, 2021, Hong Kong) Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.
China Tech Digest: Didi Launched Driverless Vehicle Project; Dingdong Maicai Raised US$700M Series D Round chinamoneynetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chinamoneynetwork.com Daily Mail and Mail on Sunday newspapers.
Hive Ventures invests in InfuseAI and 15 more deal updates from Greater China
April 6, 2021
Taiwanese machine learning startup InfuseAI has secured a $4.3 million Series A round funding led by the iPhone manufacturer Wistron Corporation, per a company statement on Tuesday.
Taiwan-based, tech-driven global VC Hive Ventures partnering Taiwan Venture Capital Group and Silicon Valley Taiwan Investment also joined the current round.
InfuseAI is gearing up to foray into the Japan market, followed by Southeast Asia.
InfuseAI, set up in 2018, offers a gamut of development and data analysis services to enterprises in fintech and manufacturing sectors. Now its flagship solution, PrimeHub is an all-in-one, on-premise machine learning (ML) platform that can help companies maximise machine learning operations (MLOps).
Chinese online grocer Dingdong Maicai nets $700m funding co-led by DST dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.